Skip to main content
OpenTrials

Clinical trial condition

Lung Diseases, Obstructive

Explore clinical trials studying Lung Diseases, Obstructive. Study availability and eligibility vary by location and protocol.

7,959 public trials 737 recruiting studies
Refine in advanced search Browse all conditions

Lung Diseases, Obstructive trial results

Completed

Evaluation of Tiotropium 2.5 and 5 µg Once Daily Delivered Via the Respimat Inhaler Compared to Placebo in Patient With Moderate to Severe Persistent Asthma

NCT01340209

Conditions
Asthma, Bronchial Diseases, Hypersensitivity, +6 more
Locations
  • 205.464.81020 Boehringer Ingelheim Investigational Site Asahikawa, Hokkaido, Japan
  • 205.464.81031 Boehringer Ingelheim Investigational Site Atsugi, Kanagawa, Japan
  • 205.464.81029 Boehringer Ingelheim Investigational Site Chigasaki, Kanagawa, Japan
  • 205.464.81011 Boehringer Ingelheim Investigational Site Chino, Nagano, Japan
View all 55 locations
View Trial Details
Completed

Actuation Indicator Trial in Patients With COPD

NCT00928746

Conditions
Chronic Disease, Disease Attributes, Lung Diseases, +5 more
Locations
  • 244.2507.0107 Boehringer Ingelheim Investigational Site Lafayette, Louisiana, United States
  • 244.2507.0106 Boehringer Ingelheim Investigational Site Easley, South Carolina, United States
  • 244.2507.0102 Boehringer Ingelheim Investigational Site Gaffney, South Carolina, United States
  • 244.2507.0104 Boehringer Ingelheim Investigational Site Greenville, South Carolina, United States
View Trial Details
Completed

BI 1744 CL With Respimat Once Daily Versus Twice Daily in COPD

NCT00846768

Conditions
Chronic Disease, Disease Attributes, Lung Diseases, +5 more
Locations
  • 1222.26.32008 Boehringer Ingelheim Investigational Site Genk, Belgium
  • 1222.26.32006 Boehringer Ingelheim Investigational Site Ghent, Belgium
  • 1222.26.32007 Boehringer Ingelheim Investigational Site Hasselt, Belgium
  • 1222.26.31002 Boehringer Ingelheim Investigational Site Eindhoven, Netherlands
View Trial Details
Completed

Characterization of 24 Hour Spirometry Profiles of Inhaled BI 1744 CL and Inhaled Foradil in Patients With Chronic Obstructive Pulmonary Disease

NCT00931385

Conditions
Chronic Disease, Disease Attributes, Lung Diseases, +5 more
Locations
  • 1222.24.24011 Boehringer Ingelheim Investigational Site Tampa, Florida, United States
  • 1222.24.24009 Boehringer Ingelheim Investigational Site Overland Park, Kansas, United States
  • 1222.24.24007 Boehringer Ingelheim Investigational Site Lafayette, Louisiana, United States
  • 1222.24.24002 Boehringer Ingelheim Investigational Site Cincinnati, Ohio, United States
View Trial Details

Related conditions